DaVita (NYSE:DVA) Updates FY 2025 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.440. The company issued revenue guidance of -.

DaVita Price Performance

Shares of DVA stock traded up $5.45 during trading hours on Thursday, hitting $177.45. 1,008,829 shares of the company’s stock were exchanged, compared to its average volume of 577,985. The stock’s 50-day moving average is $161.15 and its 200-day moving average is $157.11. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a market cap of $14.55 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94. DaVita has a 52 week low of $118.56 and a 52 week high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. As a group, research analysts forecast that DaVita will post 9.71 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.